No Data
Earnings Call: Rhythm Pharmaceuticals Has Reported a Successful Third Quarter in 2024
Rhythm Pharmaceuticals Shares Are Trading Higher After Multiple Firms Maintained a Buy Rating on the Stock and Raised Their Respective Price Targets.
Rhythm Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $64 to $72
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Rhythm Pharmaceuticals' Positive Outlook and Increased Price Target Driven by Imcivree's Performance and Upcoming Phase 3 Trial Results
No Data
No Data